NCT00684502View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Pain
Interventions
DRUG

AZD2066

Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.

DRUG

Placebo

Administered orally as a solution once per day on day 1, and then day 3 through to day 12.

Trial Locations (1)

Unknown

Research Site, Stockholm

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY